Malignant melanoma in the 21st century, part 2: Staging, prognosis, and treatment

Mayo Clinic Proceedings

Volumn 82, Issue 4, 2007, Pages 490-513

  Markovic, Svetomir N ^a,b   Erickson, Lori A ^a   Rao, Ravi D ^a   Weenig, Roger H ^a   Pockaj, Barbara A ^d   Bardia, Aditya ^a   Vachon, Celine M ^c   Schild, Steven E ^d   McWilliams, Robert R ^a   Hand, Jennifer L ^a   Laman, Susan D ^d   Kottschade, Lisa A ^a   Maples, William J ^e   Pittelkow, Mark R ^a   Pulido, Jose S ^a   Cameron, J Douglas ^a   Creagan, Edward T ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Mayo Clinic   (United States)

^d MAYO CLINIC   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DACARBAZINE; EVEROLIMUS; FUMAGILLOL CHLOROACETYLCARBAMATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELACINE; MELANOMA VACCINE; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; SEMAXANIB; SORAFENIB; SQUALAMINE; SUNITINIB; TANOMASTAT; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VINBLASTINE;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INVASION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHOROID MELANOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; HYPOTENSION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MITOSIS RATE; MULTIMODALITY CANCER THERAPY; OLIGURIA; PROGNOSIS; RECOMMENDED DRUG DOSE; SENTINEL LYMPH NODE BIOPSY; THROMBOCYTOPENIA; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 34047199547     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.4.490     Document Type: Conference Paper

References (253)

1. Markovic SN, Erickson LA, Rao RD, et al, Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82:364-380.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
3. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
4. Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1-45.
5. Lund RH, Ihnen M. Malignant melanoma: clinical and pathologic analysis of 93 cases: is prophylactic lymph node dissection indicated? Surgery. 1955;38:652-659.
6. Lane N, Lattes R, Malm J. Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults. Cancer. 1958;11:1025-1043.
7. Petersen NC, Bodenham DC, Lloyd OC. Malignant melanomas of the skin: a study of the origin, development, aetiology, spread, treatment, and prognosis. I. Br J Plast Surg. 1962;15:49-94.
8. Mehnert JH, Heard JL. Staging of malignant melanomas by depth of invasion: a proposed index to prognosis. Am J Surg. 1965;110:168-176.
9. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969:29:705-727.
10. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
11. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-742.
12. Balch CM, Soong S, Ross MI, et al, Intergroup Melanoma Surgical Trial. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann Surg Oncol. 2000;7:87-97.
13. Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer. 1979;43:883-888.
14. Clark WH Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
15. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study [published correction appears in Cancer. 1997;79:423]. Cancer. 1996;78:427-432.
16. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995;75:2484-2491.
17. Rigel DS, Rogers GS, Friedman RJ. Prognosis of malignant melanoma. Dermatol Clin. 1985;3:309-314.
18. Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer. 2002;38:511-516.
19. Sondergaard K, Schou G. Prognostic factors in primary cutaneous malignant melanoma. Am J Dermatopathol. 1985;7(suppl):1-4.
20. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases: a multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol. 1985;406:179-195.
21. Sondergaard K, Schou G. Therapeutic and clinico-pathological factors in the survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I: a multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol. 1985;408:249-258.
22. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg. 1994;129:316-324.
23. Lock-Andersen J, Hou-Jensen K, Hansen JP, Jensen NK, Sogaard H, Andersen PK. Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg. 1995;29:141-148.
24. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.
25. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma, II: prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979;86:343-351.
26. Cascinelli N, Marubini E, Morabito A, Bufalino R. Prognostic factors for stage I melanoma of the skin: a review. Stat Med. 1985;4:265-278.
27. Marghoob AA, Koenig K, Bittencourt FV, Kofp AW, Bart RS. Breslow thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer. 2000;88:589-595.
28. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484-1491.
29. Day CL Jr, Harrist TJ, Gorstein F, et al. Malignant melanoma: prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194:108-112.
30. Harrist TJ, Rigel DS, Day CL Jr, et al. "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer. 1984;53:2183-2187.
31. Leon P, Daly JM, Synnestvadt M, Schultz DJ, Elder DE, Clark WH Jr. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg. 1991;126:1461-1468.
32. Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of microscopic satellites of the primary and extracaspular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002;20:2053-2057.
33. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
34. Balch CM, Buzaid AC, Soong SJ, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003;21:43-52.
35. Yan S, Brennick JB. False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes. Am J Surg Pathol. 2004;28:596-600.
36. Clark WH Jr, Elder DE, Guerry D IV, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984;15:1147-1165.
37. Crowson AN, Magro CM, Mihm MC Jr, eds. The Melanocytic Proliferations: A Comprehensive Textbook of Pigmented Lesions. New York, NY: Wiley-Liss; 2001.
38. Elder DE, Guerry D IV, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol. 1984;6(suppl):55-61.
39. Guerry D IV, Synnestvedt M, Elder DE, Schultz D. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol. 1993;100:342S-345S.
40. Lefevre M, Vergier B, Balme B, et al. Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol. 2003;27:717-724.
41. Oliveira Filho RS, Ferreira LM, Biasi LJ, Enokihara MM, Paiva GR, Wagner J. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003 Mar;36:347-350. Epub 2003 Mar 7.
42. Taran JM, Heenan PJ. Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. Cancer. 2001;91:1822-1825.
43. Otto FJ, Goldmann T, Biess B, Lippold A, Suter L, Westhoff U. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters. Oncology. 1999;56:208-214.
44. Day CL Jr, Mihm MC Jr, Lew RA, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.39 mm): a conceptual model for tumor growth and metastasis. Ann Surg. 1982;195:35-43.
45. Byers HR, Bhawan J. Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Hematol Oncol Clin North Am. 1998;12:717-735.
46. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268-273.
47. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
48. Karjalainen JM, Eskelinen MJ, Nordling S, Lipponen PK, Alhava EM, Kosma VM. Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. Br J Cancer. 1998;77:1917-1925.
49. Massi D, Borgobnoni L, Franchi A, Martini L, Reali UM, Santucci M. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res. 2000;10:153-164.
50. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging [published correction appears in J Clin Oncol. 2005;23:656]. J Clin Oncol. 2004 Sep 15;22:3668-3676. Epub 2004 Aug 9.
51. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056.
52. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005 Jun;12:449-458. Epub 2005 Apr 19.
53. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006 Apr;13:533-541. Epub 2006 Mar 7.
54. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR III, Leong SP. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998;134:983-987.
55. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology. 1992;20:315-322.
56. Ronan SG, Eng AM, Briele HA, Shioura NN, Gas Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123:1326-1330.
57. Paladugu RR, Yonemoto RH. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983;118:1-44.
58. Naruns PL, Nizze JA, Cochran AJ, Lee MB, Morton DL. Recurrence potential of thin primary melanomas. Cancer. 1986;57:545-548.
59. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology. 1990;17:389-395.
60. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603-608.
61. Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal "thin" malignant melanoma: identifying patients at risk. Ann Surg. 1988;208:150-161.
62. Zettersten E, Sagebiel RW, Miller JR III, Tallapureddy S, Leong SP, Kashani-Sabet M. Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer. 2002;94:1049-1056.
63. Straume O, Akslen LA. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1996;78:1211-1219.
64. Barnhill R, Dy K, Lugassy C. Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis. J Invest Dermatol. 2002;119:705-706.
65. Barnhill RL, Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology. 2004;36:485-490.
66. Lugassy C, Haroun RI, Brem H, et al. Pericytic-like angiotropism of glioma and melanoma cells. Am J Dermatopathol. 2002;24:473-478.
67. Clemente CG, Mihm MC Jr, Bufalina R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
68. Elder DE, Guerry D IV, VanHorn M, et al. The role of lymph node dissection for clinical stage malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer. 1985;56:413-418.
69. Tuthill RJ, Undger JM, Liu PY, Flaherty LE, Sondak VK, Southwest Oncology Group. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002;118:504-511.
70. Masback A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res. 2001;11:435-445.
71. Barnhill RL, Piepkorn M, Busam KJ. Pathology of Melanocytic Nevi and Malignant Melanoma. 2nd ed. New York, NY: Springer; 2004:238-394.
72. McGovern VJ, Cochran AJ, Van der Esch EP, Little JH, MacLennan R. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18:12-21.
73. Pack GT, Miller TR. Metastatic melanoma with indeterminate primary site: report of two instances of long-term survival. JAMA. 1961;176:55-56.
74. Brogelli L, Reali UM, Moretti S, Urso C. The prognostic significance of histologic regression in cutaneous melanoma [published correction appears in Melanoma Res. 1992;2:213]. Melanoma Res. 1992;2:87-91.
75. Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? Am J Dermatopathol. 2003;25:371-376.
76. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma: a histologic feature without independent prognostic significance. Cancer. 1985;56:2287-2291.
77. Lugassy C, Kleinman HK, Fernandez PM, et al. Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis. J Invest Dermatol. 2002;119:703-704.
78. Melanoma of the skin. In: Green FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:209-220.
79. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma [published correction appears in N Engl J Med. 2004;351:2461]. N Engl J Med. 2004;351:998-1012.
80. Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg. 2004;139:831-836.
81. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570-579.
82. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol. 2006 Apr;13:525-532. Epub 2006 Feb 15.
83. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm [published correction appears in N Engl J Med. 1991;325:292]. N Engl J Med. 1988;318:1159-1162.
84. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol. 1998;5:322-328.
85. Pennington BE, Leffel DJ. Mohs micrographic surgery: established uses and emerging trends. Oncology (Williston Park). 2005;19:1165-1171.
86. Karakousis CP, Goumas W, Rao U, Driscoll DL. Axillary node dissection in malignant melanoma. Am J Surg. 1991;162:202-207.
87. Balch CM, Soong SJ, Smith T, et al, Investigators from the Intergroup Melanoma Surgical Trial. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101-108.
88. Reintgen DS, Cox EB, McCarty KS Jr, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg. 1983;198:379-385.
89. McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet. 1985;161:575-580.
90. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982;196:677-684.
91. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697-705.
92. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627-630.
93. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F, WHO Melanoma Programme. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet. 1998;351:793-796.
94. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-263.
95. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
96. Albertini JJ, Cruse CW, Raraport D, et al. Intraoperative radio-lymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223:217-224.
97. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 1995;5:255-260.
98. Norman J, Cruse CW, Espinosa C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162:432-437.
99. Joseph E, Brobeil A, Glass F, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol. 1998;5:119-125.
100. Morton DL, Thompson JF, Essner R, et al, Multicenter Selective Lymphadenectomy Trial Group. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg. 1999;230:453-463.
101. Morton DL, Chan AD. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? J Am Coll Surg. 1999;189:214-223.
102. Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg. 1997;132:666-672.
103. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-3684.
104. Karakousis CP, Grigoropoulos P. Sentinel node biopsy before and after wide excision of the primary melanoma. Ann Surg Oncol. 1999;6:785-789.
105. Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL. Prognostic implications of thick (≥4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002;9:754-761.
106. Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (≥4-mm) melanoma: should we be doing it? Ann Surg Oncol. 2003;10:408-415.
107. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9:637-645.
108. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. 1998;280:1410-1415.
109. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol. 2004;22:3989-3996.
110. Cormier JN, Xing Y, Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005;23:6054-6062.
111. Morton DL, Thompson JF, Cochran AJ, Essner R, Elashoff R, Group MSLT. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma [abstract]. J Clin Oncol. 2005;23(suppl):710s. Abstract 7500.
112. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139:961-966.
113. Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89:1983-1991.
114. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
115. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13:2776-2783.
116. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
117. Stoutenburg JP, Schrope B, Kaufman HL. Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther. 2004;4:823-835.
118. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U, Eastern Cooperative Oncology Group. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677.
119. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
120. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718.
121. Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994;343:913-914.
122. Kleeberg UR, Suciu S, Brocker EB, et al, EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40:390-402.
123. Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G. Postsurgical adjuvant therapy for melanoma: evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer. 1997;79:2354-2360.
124. Grob JJ, Dreno B, de la Salmoniere P, et al, French Cooperative Group on Melanoma. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet. 1998;351:1905-1910.
125. Pehamberger H, Soyer HP, Steiner A, et al, Austrian Malignant Melanoma Cooperative Group. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 1998;16:1425-1429.
126. Eggermont AM, Suciu S, MacKie R, et al, EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366:1189-1196.
127. Hauschild A, Weichenthal M, Balda BR, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21:2883-2888.
128. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2000;18:1614-1621.
129. Berd D, Maguire HC Jr, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 1997;15:2359-2370.
130. Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res. 1995;139:337-348.
131. DiFronzo LA, Gupta RK, Essner R, et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol. 2002;20:3242-3248.
132. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1;22:403-415. Epub 2003 Dec 22.
133. Balch CM, Sober AJ, Soong SJ, Gershenwald JE, AJCC Melanoma Staging Committee. The new melanoma staging system. Semin Cutan Med Surg. 2003;22:42-54.
134. Carter SK, Friedman MA. 5-(3,3-dimethyl-1-triazeno)-imidazole-4- carboxamide (DTIC, DIC, NSC-45388): a new antitumor agent with activity against malignant melanoma. Eur J Cancer. 1972;8:85-92.
135. Bellett RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat Rep. 1976;60:595-600.
136. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [published correction appears in J Clin Oncol. 2000;18:2351]. J Clin Oncol. 2000;18:158-166.
137. Mule JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res. 1986;46:676-683.
138. Topalian SL, Rosenberg SA. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin 2. Acta Haematol. 1987;78(suppl):75-76.
139. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res. 1986;46:4973-4978.
140. Lotze MT, Rosenberg SA. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology. 1986;172:420-437.
141. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823-1841.
142. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474-484.
143. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer [published correction appears in J Natl Cancer Inst. 1993;85:1091]. J Natl Cancer Inst. 1993;85:622-632.
144. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
145. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
146. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci1 Am. 2000;6(suppl):S11-S14.
147. Atkins MB. Interleukin-2 in metastatic melanoma: establishing a role. Cancer J Sci Am. 1997;3(suppl):S7-S8.
148. Atkins MB. Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am. 2000;6(suppl):S8-S10.
149. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol. 1994;21(suppl):23-28.
150. Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997;3(suppl):S9-S15.
151. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologies. Curr Opin Oncol. 1997;9:205-213.
152. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy continuing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996;7:827-835.
153. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759.
154. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol. 1997;24(suppl):S39-S43.
155. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045-2052.
156. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res. 2006;12:2353s-2358s.
157. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol. 2002;20:4549-4554.
158. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988;48:5883-5893.
159. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol. 1990;8:856-869.
160. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20:2058-2066.
161. Sosman JA, Sondak VK. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines. 2003;2:353-368.
162. Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: melacine. Semin Cancer Biol. 2003;13:409-415.
163. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,
164. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24:16-24. Epub 2005 Dec 5.
165. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003;21:3351-3356.
166. Hwu WJ, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial [published correction appears in J Clin Oncol. 2002;20:3361]. J Clin Oncol. 2002;20:2610-2615.
167. Kudva GC, Collins BT, Dunphy FR II. Thalidomide for malignant melanoma. N Engl J Med. 2001;345:1214-1215.
168. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2001;2:634-635.
169. Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 2004;14:57-62.
170. Reiriz AB, Richter MF, Fernandes S, et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. 2004;14:527-531.
171. Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005;103:2590-2597.
172. Molina JR, Reid JM, Erlichman C, et al. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metaloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs. 2005;16:997-1002.
173. Weng DE, Masci PA, Radka SF, et al. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol Cancer Ther. 2005;4:948-955.
174. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU 5416 in advanced melanoma. Clin Cancer Res. 2004;10:4048-4054.
175. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitors SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res. 2003;9:1648-1655.
176. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-961.
177. Bhargava P, Marshall JL, Dahut W, et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res. 2001;7:3912-3919.
178. Bhargava P, Marshall JL, Rizvi N, et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res. 1999;5:1989-1995.
179. Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005;104:1045-1048.
180. Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Melanoma Res. 2003;13:531-536.
181. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25:283-286.
182. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106:375-382.
183. Danson S, Lorigan P. Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs. 2005;65:733-743.
184. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006;66:1611-1619.
185. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci. 2005;1059:16-25.
186. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27;417:949-954. Epub 2002 Jun 9.
187. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000.
188. Schreck R, Rapp UR. Raf kinases: oncogenesis and drug discovery. Int J Cancer. 2006;119:2261-2271.
189. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15;100:4712-4717. Epub 2003 Apr 7.
190. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10;23:8968-8977. Epub 2005 Oct 3.
191. Deiner-West M, Earle JD, Fine SL, et al, Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. Arch Ophthalmol. 2001;119:951-965. COMS Report No. 17.
192. Diener-West M, Earle JD, Fine SL, et al, Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. Arch Ophthalmol. 2001;119:969-982. COMS Report No. 18.
193. Harwood AR, Lawson VG. Radiation therapy for melanomas of the head and neck. Head Neck Surg. 1982;4:468-474.
194. Tsang RW, Liu FF, Wells W, Payne DG. Lentigo maligna of the head and neck: results of treatment by radiotherapy. Arch Dermatol. 1994;130:1008-1012.
195. Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000;43:477-482.
196. Johanson CR, Harwood AR, Cummings BJ, Quirt I. 0-7-21 radiotherapy in nodular melanoma. Cancer. 1983;15:226-232.
197. Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer. 1978;42:2206-2210.
198. Ang KK, Byers RM, Peters LJ, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma: preliminary results. Arch Otolaryngol Head Neck Surg. 1990;116:169-172.
199. Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys. 1994;30:795-798.
200. Ballo MT, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am. 2003;83:323-342.
201. Geara FB, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am. 1996;76:1383-1398.
202. Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005;27:718-721.
203. Ballo MT, Strom EA, Zagars GK, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002;52:964-972.
204. Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002;20:4555-4558.
205. Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003;97:1789-1796.
206. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park). 2004;18:99-107.
207. Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004;11:1079-1084.
208. Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64:106-113. Epub 2005 Sep 22.
209. Amozorrutia-Alegria V, Bravo-Ortiz JC, Vazquez-Viveros J, et al. Epidemiological characteristics of retinoblastoma in children attending the Mexican Social Security Institute in Mexico City, 1990-1994. Paediatr Perinat Epidemiol. 2002;16:370-374.
210. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys. 1985;11:1837-1839.
211. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20:429-432.
212. Meier S, Baumert BG, Maier T, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004;27:145-149.
213. Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005;112:1784-1789.
214. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75-84.
215. Infante de German-Ribon R, Singh AD, Arevalo JF, Driebe W, Eskin T. Choroidal melanoma with oculodermal melanocytosis in Hispanic patients. Am J Ophthalmol. 1999;128:251-253.
216. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am. 2005;18:143-150.
217. Singh AD, Kivela T. The collaborative ocular melanoma study. Ophthalmol Clin North Am. 2005;18:129-142.
218. Diener-West M, Reynolds SM, Agugliaro DJ, et al, Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639-1643.
219. Singh AD, Damato B, Howard P, Harbour JW. Uveal melanoma: genetic aspects. Ophthalmol Clin North Am. 2005;18:85-97.
220. Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006;66:4602-4609.
221. Mehaffey MG, Folberg R, Meyer M, et al. Relative importance of quantifying area and vascular patterns in uveal melanomas. Am J Ophthalmol. 1997;123:798-809.
222. Folberg R, Fleck M, Mehaffey MG, et al. Mapping the location of prognostically significant microcirculatory patterns in ciliary body and choroidal melanomas. Pathol Oncol Res. 1996;2:229-236.
223. Folberg R, Mehaffey M, Gardner LM, Meyer M, Rummelt V, Pe'er J. The microcirculation of choroidal and ciliary body melanomas. Eye. 1997;11:227-238.
224. Spire M, Devouassoux MS, Kodjikian L, Janin-Magnificat H, Fleury J, Grange JD. Primary transpupillary thermotherapy for 18 small posterior pole uveal melanomas. Am J Ophthalmol. 2006;141:840-849.
225. Mueller AJ, Freeman WR, Schaller UC, Kampik A, Folberg R. Complex microcirculation patterns detected by confocal indocyanine green angiography predict time to growth of small choroidal melanocytic tumors: MuSIC Report II. Ophthalmology. 2002;109:2207-2214.
226. Buerk BM, Pulido JS, Chiong I, et al. Vascular perfusion of choroidal melanoma by 3.0 tesla magnetic resonance imaging. Trans Am Ophthalmol Soc. 2004;102:209-215.
227. Lee ES, Baratz KH, Pulido JS, Salomao DR. Expression of vascular endothelial growth factor in iris melanoma. Arch Ophthalmol. 2006;124:1349-1350.
228. Nordlund JR, Robertson DM, Herman DC. Ultrasound biomicroscopy in management of malignant iris melanoma. Arch Ophthalmol. 2003;121:725-727.
229. Geisse LJ, Robertson DM. Iris melanomas. Am J Ophthalmol. 1985;99:638-648.
230. Conway RM, Chua WC, Qureshi C, Billson FA. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol. 2001;85:848-854.
231. Autier P, Dore JF, Reis AC, et al. Sunscreen use and intentional exposure to ultraviolet A and B radiation: a double blind randomized trial using personal dosimeters. Br J Cancer. 2000;83:1243-1248.
232. Umeda M, Komatsubara H, Shibuya Y, Yokoo S, Komori T. Premalignant melanocytic dysplasia and malignant melanoma of the oral mucosa. Oral Oncol. 2002;38:714-722.
233. Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res. 2004;10:3444-3447.
234. Wong CW, Fan YS, Chan TL, et al, Cancer Genome Project. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol. 2005;58:640-644.
235. Edwards RH, Ward MR, Wu H, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet. 2004;41:270-272.
236. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147.
237. Muchmore JH, Mizuguchi RS, Lee C. Malignant melanoma in American black females: an unusual distribution of primary sites. J Am Coll Surg. 1996;183:457-465.
238. Takagi M, Ishikawa G, Mori W. Primary malignant melanoma of the oral cavity in Japan: with special reference to mucosal melanosis. Cancer. 1974;34:358-370.
239. Rogers RS III, Gibson LE. Mucosal, genital, and unusual clinical variants of melanoma. Mayo Clin Proc. 1997;72:362-366.
240. Liang KV, Sanderson SO, Nowakowski GS, Arora AS. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc. 2006;81:511-516.
241. Hicks MJ, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol. 2000;36:152-169.
242. Wada H, Nemoto K, Ogawa Y, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int Radiat Oncol Biol Phys. 2004;59:495-500.
243. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005;6:438-439.
244. Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004;100:1478-1483.
245. Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. J Clin Oncol. 2004;22(suppl):711s. Abstract 7507.
246. Chang P, Knapper WH. Metastatic melanoma of unknown primary. Cancer. 1982;49:1106-1111.
247. Dasgupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynceol Obstet. 1963;117:341-345.
248. Schlagenhauff B, Stroebel W, Ellwanger U, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendation for initial staging examinations. Cancer. 1997;80:60-65.
249. Ross MI, Cormier JN, Xing Y, Gershenwald JE, Lee JE, Mansfield PF. Prognosis and survival outcomes in melanoma patients with unknown primary site (MUP) [abstract]. J Clin Oncol. 2004;22(suppl):721s. Abstract 7544.
250. Baab GH, McBride CM. Malignant melanoma: the patient with an unknown site of primary origin. Arch Surg. 1975;110:896-900.
251. Anbari KK, Schuchter LM, Bucky LP, et al, University of Pennsylvania Pigmented Lesion Study Group. Melanoma of unknown primary site: presentation, treatment, and prognosis: a single institution study. Cancer. 1997;79:1816-1821.
252. Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg. 1987;122:1380-1383.
253. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer. 1998;82:1160-1166.